Email Alert RSS
Volume 13 Issue 4
Jul.  2022
Turn off MathJax
Article Contents
Abstract
References
Related Articles
LUO Xiangchong, WANG Zhouqing, LI Qiongyan, MAO Guibing, AN Le, ZHU Jiahong, TAO E'hong, SUN Lifei, WANG Shengfei, LI Gaofeng. Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 679-686. DOI: 10.12290/xhyxzz.2021-0691
Citation: LUO Xiangchong, WANG Zhouqing, LI Qiongyan, MAO Guibing, AN Le, ZHU Jiahong, TAO E'hong, SUN Lifei, WANG Shengfei, LI Gaofeng. Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 679-686. DOI: 10.12290/xhyxzz.2021-0691
shu

Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors

  • 1.

    Department of Cardiothoracic Surgery, Qujing Second People's Hospital, Qujing, Yunnan 655000, China

  • 2.

    Department of Second Thoracic Surgery, Yunnan Cancer Hospital, Kunming 650118, China

Funds: 

National Natural Science Foundation of China 81760554

The"Famous Doctor"Special Project of Ten Thousand People Plan of Yunnan Province C20096

Medical Leading Talents Training Program of Yunnan Provincial Health Commission L-2019028

More Information
  • Corresponding author:

    LI Gaofeng, E-mail: ligaofenghl@126.com

  • Received Date: October 12, 2021
  • Accepted Date: November 22, 2021
  • Available Online: June 26, 2022
  • Issue Publish Date: July 29, 2022
    Graphical Abstract
    • Abstract
  • In recent years, immunotherapy has made breakthroughs in the field of malignant tumors, and more and more novel immune checkpoint inhibitors have been developed, revolutionizing the first-line, second-line and post-line treatment options for malignant tumors. Tislelizumab is a domestically developed inhibitor of programmed death-1 (PD-1). The drug has shown good antitumor potential and safety in classical Hodgkin's lymphoma, uroepithelial carcinoma, non-small cell lung cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma and gastric cancer/gastroesophageal junction carcinoma. In this review, the structure and mechanism of action, pharmacodynamics and pharmacokinetics, clinical research and adverse reactions of tislelizumab are reviewed to provide reference for clinical application.
    • FullText(HTML)
    • References (44)
  • [1]
    Siegel KL, Miller KD, Jemal A, et al. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70: 7-30. DOI: 10.3322/caac.21590
    [2]
    Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy[J]. Int J Clin Oncol, 2020, 25: 790-800. DOI: 10.1007/s10147-019-01588-7
    [3]
    Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer[J]. Int J Clin Oncol, 2020, 25: 818-830.
    [4]
    Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy[J]. Int J Clin Oncol, 2020, 25: 790-800. DOI: 10.1007/s10147-019-01588-7
    [5]
    Keam SJ. Toripalimab: first global approval[J]. Drugs, 2019, 79: 573-578. DOI: 10.1007/s40265-019-01076-2
    [6]
    Hoy SM. Sintilimab: first global approval[J]. Drugs, 2019, 79: 341-346.
    [7]
    Markham A, Keam SJ. Camrelizumab: first global approval[J]. Drugs, 2019, 79: 1355-1361. DOI: 10.1007/s40265-019-01167-0
    [8]
    Lee A, Keam SJ. Tislelizumab: first approval[J]. Drugs, 2020, 80: 617-624.
    [9]
    Pinto JA, Raez LE, Oliveres H, et al. Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer[J]. Expert Opin Biol Ther, 2019, 19: 509-515. DOI: 10.1080/14712598.2019.1610380
    [10]
    Jayesh D, Benjamin M, Michael F, et al. Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an inves-tigational anti-PD-1 antibody, in a first-in-human Phase Ⅰ study[J]. Cancer Res, 2019, 79: CT084.
    [11]
    Lee SH, Lee HT, Lim H, et al. Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy[J]. Biochem Biophys Res Commun, 2020, 527: 226-231.
    [12]
    Zhang T, Song X, Xu L, et al. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions[J]. Cancer Immunol Immunother, 2018, 67: 1079-1090.
    [13]
    Shen L, Guo J, Zhang Q, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non- comparative, phase 1/2 study[published correction appears in J Immunother Cancer[J]. J Immunother Cancer, 2020, 8: e000437.
    [14]
    Lee SH, Lee HT, Lim H, et al. Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy[J]. Biochem Biophys Res Commun, 2020, 527: 226-231.
    [15]
    Wu CY, Budha N, Gao Y, et al. Tislelizumab exposure-response analyses of efficacy and safety in patients with advanced tumors[J]. Ann Oncol, 2019: v182-v183.
    [16]
    Lee HT, Lee SH, Heo YS. Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology[J]. Molecules, 2019, 24: 1190-1195.
    [17]
    Feng YC, Hong Y, Sun HZ, et al. The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is diferentiated from pembrolizumab and nivolumab[J]. Cancer Res, 2019, 79: 2383.
    [18]
    Zhang T, Song J, Li YC, et al. Anti-human PD-1 antibody BGB-A317 exhibits potent immune cell activation[J]. Cancer Res, 2016, 76: 2226.
    [19]
    Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, bms-936558, and in vivo toxicology in non-human primates[J]. Cancer Immunol Res, 2014, 2: 846-885.
    [20]
    Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma[J]. Expert Opin Drug Metab Toxicol, 2016, 12: 1247-1253.
    [21]
    Ansell SM. Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management[J]. Am J Hematol, 2020, 95: 978-989.
    [22]
    Chen J, Zhang H, Zhu L, et al. Tislelizumab for the treatment of classical Hodgkin's lymphoma[J]. Drugs Today (Barc), 2020, 56: 781-785.
    [23]
    Takahara T, Murase Y, Tsuzuki T. Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes[J]. Pathology, 2021, 53: 56-66.
    [24]
    Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial[J]. Lancet, 2017, 389: 67-76.
    [25]
    Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study[J]. Lancet Oncol, 2017, 18: 1483-1492.
    [26]
    Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2017, 18: 312-322.
    [27]
    Powles T, O'Donnell PH, Massard C, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study[J]. JAMA Oncol, 2017, 3: e172411.
    [28]
    Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial[J]. Lancet Oncol, 2018, 19: 51-64.
    [29]
    Ye D, Liu J, Zhou A, et al. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma[J]. Cancer Sci, 2021, 112: 305-313.
    [30]
    Koleczko S, Wolf J. Immune checkpoint inhibitors in lung cancer[J]. Internist (Berl), 2020, 61: 676-681.
    [31]
    Liu SY, Wu YL. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)[J]. Expert Opin Investig Drugs, 2020, 29: 1355-1364.
    [32]
    Wang Z, Zhao J, Ma Z, et al. A Phase 2 study of Tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients[J]. Lung Cancer, 2020, 147: 259-268.
    [33]
    Wang J, Lu S, Yu XM, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: A Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2021, 7: 709-717.
    [34]
    Lu S, Wang J, Yu Y, et al. Tislelizumab Plus Chemo-therapy as First-Line Treatment for Locally Advanced or Metas-tatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial[J]. J Thorac Oncol, 2021, 16: 1512-1522.
    [35]
    Ko KL, Mak LY, Cheung KS, et al. Hepatocellular carcinoma: recent advances and emerging medical therapies[J]. F1000Res, 2020, 9: F1000 Faculty Rev-620.
    [36]
    El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389: 2492-2502.
    [37]
    Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224): a non-rando-mised, open-label phase 2triaI[J]. Lancet Oncol, 2018, 19: 940-952.
    [38]
    Shen L, Guo J, Zhang Q, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study[J]. J Immunother Cancer, 2020, 8: e000437.
    [39]
    Qin S, Finn RS, Kudo M, et al. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma[J]. Future Oncol, 2019, 15: 1811-1822.
    [40]
    Sun J, Zheng Y, Mamun M, et al. Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors[J]. Biomed Pharmacother, 2020, 129: 110504.
    [41]
    Xu J, Bai Y, Xu N, et al. Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma[J]. Clin Cancer Res, 2020, 26: 4542-4550.
    [42]
    Wang SY, Huang XM, Bai YX, et al. Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer (NPC)[J]. J Clin Oncol, 2019, 37: 2556-2556.
    [43]
    Oh Do-Youn, Chung HC, Im YH, et al. ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress[J]. J Clin Oncol, 2020, 38: TPS3145.
    [44]
    Baek JH. Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer[J]. J Yeungnam Med Sci, 2022, 9: 62-66.
    • Related Articles

  • Related Articles

    [1]WANG Qi, CHEN Miao. Advances in Immunotargeted Therapy for Warm Autoimmune Hemolytic Anemia[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 423-430. DOI: 10.12290/xhyxzz.2024-0668
    [2]LIU Shupeng, YU Mengyang, WU Xiaofei, WANG Hongyun. Clinical Landscape of Therapeutic Cancer Vaccines: Challenges and Opportunities[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(6): 1356-1363. DOI: 10.12290/xhyxzz.2024-0130
    [3]WEN Xuejun, ZHOU Wuhao, GUO Zhide, ZHANG Xianzhong. Integrin αvβ3 Targeted Radiopharmaceutical 99mTc-RGD Combined with Anti-PD-L1 mAb to Enhance the Anti-tumor Effect in Tumor Immunotherapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 766-773. DOI: 10.12290/xhyxzz.2023-0155
    [4]LI Tao, ZHANG Kan, YANG Wenyu, LIU Lu, ZHENG Xuan, ZHANG Fan, HU Yi. Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 652-659. DOI: 10.12290/xhyxzz.2022-0617
    [5]WANG Shuo, DENG Yuntian, PENG Huan, ZHANG Xiangfeng. Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 409-415. DOI: 10.12290/xhyxzz.2022-0151
    [6]DAI Liyuan, SHI Yuankai, HAN Xiaohong. Advances in Dynamic Monitoring of Immune Checkpoint Inhibitors as the Prognostic Markers for Advanced Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 287-295. DOI: 10.12290/xhyxzz.2021-0608
    [7]HUA Yuwei, ZHAO Lin. Diagnosis and Management of Immunotherapy-related Liver Toxicity[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(5): 798-806. DOI: 10.12290/xhyxzz.2021-0138
    [8]Mei GUAN, Chun-mei BAI. Medical Treatment for Biliary Tract Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 325-333. DOI: 10.3969/j.issn.1674-9081.20190247
    [9]Han-zhong LI, Yu-shi ZHANG, Guo-yang ZHENG. Commentary on and Expectation of Tumor Immunotherapy[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(4): 289-294. DOI: 10.3969/j.issn.1674-9081.2018.04.001
    [10]Xiao-hua SHI, Zhi-yong LIANG, Huan-wen WU, Xin-yu REN, Tong-hua LIU. Effect of RNA Interference Plasmid on the Expression of Oncogene AKT2 in Pancreatic Cancer Cell Line Panc-1[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(1): 102-108. DOI: 10.3969/j.issn.1674-9081.2012.01.021

  • Cited by

    Periodical cited type(30)

    1. 倪文豪，徐丹颖，黄若冰，陈岩，王红兵. 替雷利珠单抗联合TC化疗方案治疗驱动基因阴性晚期肺腺癌的临床研究. 现代生物医学进展. 2025(01): 126-131 .
    2. 高过，华永飞，王高卿. 不同PD-1抑制剂联合仑伐替尼治疗原发性肝癌的效果对比. 现代实用医学. 2025(01): 18-21 .
    3. 林淑君，蓝佳琦，沈惠群，郭孟贤. 替雷利珠单抗联合安罗替尼治疗晚期非小细胞肺癌的临床研究. 中国医药指南. 2024(02): 27-30 .
    4. 苏展，车金辉，裴锐锋. 替雷利珠单抗较索拉非尼作为晚期不可切除肝细胞癌一线治疗的成本-效用分析. 中国药师. 2024(01): 109-116 .
    5. 刘孝凤，潘鑫福，卢洁. 替雷利珠单抗联合化疗方案治疗中晚期NSCLC疗效观察. 中国基层医药. 2024(03): 347-352 .
    6. 盖云竹，王丽娜. 替雷利珠单抗治疗不可切除晚期肺癌对疗效的提升作用. 现代医学与健康研究电子杂志. 2024(05): 60-62 .
    7. 李星辉，朱平香. 替雷利珠单抗联合化疗药物治疗晚期非小细胞肺癌的疗效及对血清肿瘤标志物的影响探讨. 中国现代药物应用. 2024(07): 91-94 .
    8. 王亚飞，张振军，宋长亮，杨琼. ERCC1、K-ras、TP-73在替雷利珠单抗联合TP化疗方案治疗非小细胞肺癌中的评估价值. 标记免疫分析与临床. 2024(03): 496-501 .
    9. 唐金路，程强，艾青，卢崯，江彬，高帆，李世超，张瑜，顾良友，李宏召. 真实世界肌层浸润性膀胱癌新辅助化免治疗的不良事件并文献复习. 临床泌尿外科杂志. 2024(06): 518-522 .
    10. 孙国辉，阿卜杜拉·阿卜迪艾尼，阿尔恒别克·吐尔拜，木拉提·库尔班，布麦热依木·依不热依木. 腹腔热灌注化疗辅助替雷利珠单抗对进展期胃癌患者免疫功能、肿瘤标志物水平的影响. 疑难病杂志. 2024(06): 641-645+652 .
    11. 谢远航. 微波消融术联合免疫治疗对中晚期非小细胞肺癌的临床疗效探讨. 中国现代药物应用. 2024(12): 50-53 .
    12. 姚荣飞，钟丁亮，黄佰权. 基于免疫细胞浸润的免疫评分模型探讨PD-1抑制剂治疗晚期肝细胞癌后生存获益. 西部医学. 2024(07): 963-967+973 .
    13. 张媛媛，刘雪利，张蕾，张晓光，成彦培. 阿帕替尼联合替雷利珠单抗治疗一线化疗失败的晚期胃癌患者疗效分析. 中国医师杂志. 2024(07): 1060-1065 .
    14. 胡敏，刘文侠，李劲松. 替雷利珠单抗治疗非小细胞肺癌免疫相关不良事件分析. 中国药物应用与监测. 2024(04): 368-371 .
    15. 宋歌，高玉骞，罗爽，田晓玲，华云旗. 替雷利珠单抗治疗晚期胃癌的疗效和安全性分析. 中国医师进修杂志. 2024(09): 846-851 .
    16. 陈锦添，陈从其，李智强，郑元振. 前列腺癌患者PD-1水平与肿瘤分期的关系. 国际泌尿系统杂志. 2024(05): 815-818 .
    17. 李艳芳，张莉霞. 替雷利珠单抗联合白蛋白结合型紫杉醇和替吉奥二线治疗晚期胃癌的效果. 临床医学研究与实践. 2024(29): 51-54 .
    18. 王子民，董宪喆，张兰. 替雷利珠单抗治疗鳞状非小细胞肺癌的药品临床综合评价. 中国病案. 2024(11): 103-108 .
    19. 王梦婕，郭小芳. 替雷利珠单抗联合舒尼替尼治疗转移性肾癌的临床疗效及生存分析. 医学临床研究. 2024(10): 1526-1529 .
    20. 刘欣，褚文静. 替雷利珠单抗治疗晚期癌症患者的疗效观察. 婚育与健康. 2023(08): 55-57 .
    21. 裴夏明，刘侃，许镇州，戴涛，黄亮，曹健，曾恭谦，叶明佶. 替雷利珠单抗注射液联合吉西他滨注射剂和顺铂注射剂治疗晚期膀胱尿路上皮癌患者的临床研究. 中国临床药理学杂志. 2023(11): 1533-1537 .
    22. 杜淑兰，石平，张再军. 替雷利珠单抗联合紫杉醇加铂类一线治疗肺鳞癌的效果. 中外医学研究. 2023(24): 15-19 .
    23. 倪春艳，张蕾. 替雷利珠单抗致过敏性休克1例. 医药导报. 2023(10): 1576-1577 .
    24. 曾艳菊. 肿瘤患者对中医饮食知识的知晓与需求分析. 中医药管理杂志. 2023(18): 41-43 .
    25. 魏明明，黄建国，石常庆. 非小细胞肺癌予以替雷利珠单抗+化疗治疗未缓解的危险因素分析. 系统医学. 2023(15): 174-177 .
    26. 黄晓鹏. 替雷利珠单抗联合改良DCF方案治疗晚期胃癌的临床研究. 实用中西医结合临床. 2023(15): 41-43+105 .
    27. 刘海英，赵广章，崔巍，胡东玉，赵静，刘志坚. 结膜恶性黑色素瘤胃转移治疗1例报道及文献复习. 中国肿瘤生物治疗杂志. 2023(10): 937-939 .
    28. 葛超杰. 替雷利珠单抗联合阿帕替尼在晚期肝癌中的应用效果. 中外医学研究. 2023(28): 141-144 .
    29. 王帆，邓泽锋，欧阳长法，邓印根，易军，余彩霞. 替雷利珠单抗治疗非小细胞肺癌患者的效果及对患者血液学指标的影响. 中国当代医药. 2023(28): 91-94 .
    30. 顾丽英，赵亮，温林春. 奥希替尼联合替雷利珠单抗治疗晚期非小细胞肺癌效果及患者生存情况. 肿瘤研究与临床. 2023(09): 653-657 .

    Other cited types(3)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1132) PDF downloads (139) Cited by(33)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close